Eric J. Ende

Eric J. Ende (board member) discloses dealings in 2 companies, chiefly Avadel Pharmaceuticals PLC and Matinas BioPharma Holdings, Inc. In total, 9 filings cover trades dated from 19 June 2021 to 12 February 2026.

No open-market sale appears; the market trades are 5 purchases worth €614k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 2 share grants.

Half of the purchases are above €152k and half below. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 12 February 2026, the filings show a transaction worth €3.9M in Avadel Pharmaceuticals PLC. The clock since the last published purchase (14 January 2025) now reads 642 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.